Raffles Medical Group Ltd
RAFLF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.88 | -0.56 | 0.21 | 1.08 |
| FCF Yield | 3.85% | 8.94% | 8.07% | 4.53% |
| EV / EBITDA | 10.63 | 12.56 | 8.31 | 14.27 |
| Quality | ||||
| ROIC | 5.07% | 7.50% | 12.36% | 7.11% |
| Gross Margin | 64.68% | 44.62% | 77.77% | 80.21% |
| Cash Conversion Ratio | 1.38 | 2.10 | 1.37 | 1.91 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.98% | -0.73% | 13.14% | 11.51% |
| Free Cash Flow Growth | -61.29% | -1.25% | 59.38% | 53.93% |
| Safety | ||||
| Net Debt / EBITDA | -1.88 | -1.65 | -0.67 | -0.41 |
| Interest Coverage | 14.27 | 19.04 | 28.46 | 19.09 |
| Efficiency | ||||
| Inventory Turnover | 24.66 | 31.46 | 9.66 | 10.71 |
| Cash Conversion Cycle | -207.03 | -155.84 | -314.51 | -451.20 |